z-logo
open-access-imgOpen Access
Androgen expression & clinicopathological features in male breast cancer
Author(s) -
Lia Pamela Rebaza Vasquez,
Carlos A. Castañeda,
Miluska Castillo,
Luis A. Bernabe,
Joselyn Sanchez,
Gabriela Calderón,
Jorge Dunstan,
Miguel De la Cruz,
José M. Cotrina,
Julio E. Abugattas,
Henry Miller,
Maria R Villa-Robles,
Nathaly Poma,
Ómar Mejìa,
Henry Gómez
Publication year - 2018
Publication title -
breast cancer management
Language(s) - English
Resource type - Journals
eISSN - 1758-1931
pISSN - 1758-1923
DOI - 10.2217/bmt-2017-0027
Subject(s) - medicine , estrogen receptor , androgen receptor , male breast cancer , breast cancer , oncology , stage (stratigraphy) , immunohistochemistry , androgen , gynecology , cancer , hormone , biology , prostate cancer , paleontology
Aim: To investigate prognostic features in male breast cancer (MBC). Methods: Clinicopathological information from 40 MBC patients was retrospectively reviewed. Androgen receptor (AR) and estrogen receptor (ER) were prospectively stained out in 22 cases and counted through software program analysis. Results: Median age was 65.5 years; most cases were Stage II (40%), Grade II (37.5%), ER ≥10% (72.5%) and PgR ≥10% (75%). AR >10% was found in 17 of 22 cases. Although AR expression was correlated with ER, there are some cells without coexpression. Axillary node involvement was associated with DFS (p = 0.001) and age (p = 0.002) was associated with overall survival. Conclusion: ER is expressed in most MBC cases and is correlated with AR. Axillary involvement and age were associated with survival.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom